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Cell division is a highly regulated process. Checkpoints can halt cell-cycle progression due to adverse conditions such
as misalignment of chromosomes to prevent missegregation. The search for new regulators of the cell cycle revealed
the mitotic checkpoint gene CHFR (checkpoint with forkhead-associated and ring finger). CHFR coordinates an early
mitotic phase by delaying chromosome condensation in response to a mitotic stress. Because aneuploidy and
chromosome instability are common in malignant breast tumors, we screened 24 breast cancer cell lines for CHFR
expression and demonstrated that 50% (12 of 24) of breast cancer cell lines had low CHFR levels. Expression of CHFR
was reactivated with the demethylating agent 5-aza-20-deoxycytidine (5-aza-dC) in two low-CHFR–expressing cell
lines. Eleven of these 12 (92%) low-CHFR–expressing cell lines had an unusually high number of condensed
chromosomes and high mitotic indices in response to nocodazole treatment. Transfection of CHFR in one of these
cancer cell lines lowered the mitotic index after nocodazole treatment. In conclusion, our data suggested that low
CHFR expression associated with high mitotic indices in response to nocodazole treatment were common in the breast
cancer cell lines studied. Additional flow cytometry studies and analysis of a protein that interacts with CHFR in vitro,
polo-like kinase 1 (PLK1), suggests that this CHFR-associated early G2/M checkpoint is complex, involving additional, as
yet unidentified, proteins. Further analysis of CHFR in breast cancer cells will be important for understanding the
complex mechanisms leading to aneuploidy and chromosomal instability observed in breast cancer.  2003 Wiley-Liss, Inc.
Key words: CHFR; checkpoint; breast cancer; G2/M, mitosis
INTRODUCTION
The somatic cell cycle is a highly regulated process
with checkpoints that maintain normal progression
through each phase and insure that each step takes
place without errors. Checkpoints monitor G1/S and
G2/M transitions where cancer related defects can
occur.Mutations thatdisrupt somecheckpointgenes
have been linked to genetic instability observed in
cancer cells [1]. CHFR (checkpoint with forkhead-
associated and ring finger) is a recently identified
checkpoint gene that functions at the early G2/M
phase [2]. G2 toM phase progression in the cell cycle
is controlled at least inpart by thecell divisioncycle2
(CDC2)/cyclin B1 complex [3]. Cyclin B1 starts to
accumulate and associates with CDC2 to form the
mitosis promoting factor (MPF) complex as cells
enter prophase [4,5]. The MPF complex is then
transported to the nucleus and kept inactive by
WEE1 and MYT1 kinases, which phosphorylate
CDC2 [6–10]. CDC25C dephosphorylates CDC2 to
activate theMPFcomplex so that thecell canproceed
into prometaphase where chromosomes condense,
nuclear envelope breaks down, and mitotic spindles
form [11–14].
Recent studies demonstrate that CHFR functions
as an important checkpoint protein early in the
G2/M transition and its activation delays the cell
cycle in prophase, preventing chromosome conden-
sation in response to a mitotic stress by prolonging
the inhibitory phosphorylation state (Tyr15) of
CDC2 in vitro [2,15]. Initial analysis indicates that
the CHFR-associated G2/M checkpoint is inacti-
vated, as demonstrated by high mitotic indices due
to lack of CHFR expression or CHFR mutations in a
neuroblastoma, an osteosarcoma, and two colon
cancer cell lines (four of eight different cancer cell
lines) [2]. Further studies also found hypermethyla-
tion of the CHFR promoter in a variety of cancer cell
lines, including esophageal, colon, lung, osteosar-
coma, central nervous system, leukemic andprimary
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tumors of the colon, lung, and esophagus [16–19]
suggesting that decreased expression is associated
with the observed malignant phenotype.
Currently it is unclear which in vivo events trigger
activation of the CHFR-associated G2/M checkpoint.
The fact that nocodazole is a microtubule depoly-
merizing agent that can activate the checkpoint
before the formation of microtubule spindles sug-
gests that early events dependent on microtubules,
such as centrosome duplication and centrosome
separation, may be monitored by this checkpoint.
Defects in centrosome duplication or separation
are already known to be associated with genetic
instability [20–22].
Because genetic instability and aneuploidy are
very common in malignant breast cancers, we
hypothesized that defects in the CHFR-associated
G2/M checkpoint could be an important step leading
to aneuploidy and genetic instability during breast
tumorigenesis. In this study,weexamined theCHFR-
associated G2/M checkpoint and expression levels of
CHFR in breast cancer cell lines to improve our un-
derstanding of this early checkpoint and to investi-
gate its potential role in mammary tumorigenesis.
MATERIALS AND METHODS
Cell Lines
SUM149, SUM159, SUM229, SUM52, SUM102,
SUM225, SUM1315, SUM185, andhumanpapilloma
virus (HPV)-immortalized nontumorigenic mam-
mary cell lines were developed and provided by SP
Ethier at the University ofMichigan Comprehensive
Cancer Center [23–26]. Other cancer cell lines
(BT20, CAL51, DU4475, Hs578T, MDA-MB361,
MDA-MB435, MCF10A, DLD-1, MCF7, MDA-
MB468, MDA-MB157, BT474, T47D, BT549, MDA-
MB231, MDA-MB453, and SK-BR-3) were obtained
from American Type Culture Collection (Manassas,
VA) and grown under recommended conditions.
RNA Isolation and Northern Blot Analysis
RNA isolation and Northern blot analysis were
performed as previously described [27]. Polymerase
chain reaction (PCR) products of 1.1 kb for CHFR (F:
CAGGATCAGGAGGATTTGGA, R: AGTCAGGACG-
GGATGTTACG) and 0.4 kb for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (F: GGGAGC-
CAAAAGGGTCATCA, R: TTTCTAGACGGCAGGTC-
AGGT) were used to generate probes by random
primingwith [a-32P] dCTP [28]. Band intensitieswere
examined by visual inspection and quantified by
densitometry (Alpha Innotech IS-1000 Digital Ima-
ging System, Version 2.00).
Conformation Sensitive Gel Electrophoresis
(CSGE) Analysis
Primers were designed to amplify CHFR coding
sequence such that the PCR products were no more
than 650 bp and they overlapped with neighboring
PCR products (Table 1). Five micrograms of RNAwas
used to generate cDNA with oligo (dT) primers with
the Superscript Preamplification System (GibcoBRL,
Rockville, MD). Reverse transcriptase (RT)-PCR pro-
ducts were electrophoresed and visualized on a 3%
agarose gel stained with ethidium-bromide. Three to
five microliters of breast cancer and HPV11-21 cell
line RT-PCR products were mixed to facilitate the
heteroduplex formation. The mixtures were dena-
tured at 958C for 5 min, allowed to reanneal at 688C
for 30 min and analyzed by CSGE as previously de-
scribed [29]. Bands were visualized after electrophor-
esis by ethidium-bromide staining. Samples that
formed heteroduplexes were electrophoresed on
agarose gels, gel purified (Qiagen, Valencia, CA), and
sequenced at theUniversity ofMichigan Sequencing
Core.
Table 1. Primer Pairs Used for the CSGE Analysis of CHFR*
Sense primer Antisense primer Size (bp) Annealing (T8C)
GGATGTGAATCCCGATGGAG GTATGCCACGTTGTGTTCCG 386 60/58/56
TGGGGATGTCATCTACTTGG AGGTCCCCATCTCCTCTCAT 500{ 56/54/52
CAGGATCAGGAGGATTTGGA TCCTGGCATCCATACTTTGC 406 56/54/52
AAGCATACCTCATCCAGCATCC AGTACAGGTGGCAGAAAGGCTG 486 60/58/56
CAGCAGTCCAGGATTACGTGTG AGCAGTCAGGACGGGATGTTACGG 501 62/60/58
AGCTTCCGTGAGCTGACCTAT AAGCTCCACAGAAGAGTCACCC 330 62/60/58
ATACAGAGGCAAGCACGTCAA GCAGTTTTGGACATTGGAAGGTT 638 62/60/58
CTGGGAAAACCACAGCATTT CAAGGAGCGACTAACTTGGC 245 58
TCCAAAACTGCTAACCCTCG GACATGGCAAAGCTAGCACA 323 58
CTTTGCCATGTCATCTGGAA CAAACGCGGCTCATTTATTA 236 58
*CSGE, conformation sensitive gel electrophoresis; CHFR, checkpoint with forkhead-associated and ring finger.
Some polymerase chain reactions (PCRs) included three cycles with the first annealing temperature, followed by three cycles at the middle
temperature and 29 cycles at the lowest annealing temperature or 35 cycles with a single annealing temperature.
{Denotes a PCR product that was initially predicted to be 387 bp according to NM_018223, however, this primer set amplified a 500 bp
product which is consistent with AF170724.
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Methylation and Histone Modification Analysis
Cells were treated with 10 mM 5-aza-20-deoxycyti-
dine (5-aza-dC) (Sigma, St. Louis, MO) for 96 h or
with 0.5 mM trichostatin A (TSA) (Sigma) for 24 h.
Medium was aspirated off and replaced every 24 h
with freshmediumfor5-aza-dCtreatment.RNAfrom
treated anduntreated cells was collected as described
above at the end of incubation and analyzed by
Northern blot analysis for CHFR expression.
Mitotic Index Analysis
Actively growingbreast cancer cell lines at 70–80%
confluencywere treatedwith 200 ng/mLnocodazole
(Sigma) [1] for 16 h [2]. After 16 h, the media were
aspirated off and cells were rinsed and trypsinized
according to manufacturer’s suggestions prior to
incubation with a hypotonic solution of 0.075 M
potassium chloride for 20 min. After centrifugation
at 800 g for 5min, the potassium chloride solution
was discarded and cells were fixed in 3:1 methanol
and glacial acetic mixture. Cells were dropped onto
microscope slides and stained with 0.2mg/L Giemsa
stain (GibcoBRL) for 10 min, after which the slides
were rinsed with phosphate buffered saline. Nine
hundred cells were counted on average for each cell
line. Mitotic indices were calculated based on the
percentage of cells that were in any stage of mitosis
with visibly condensed chromosomes as analyzed by
lightmicroscopy.Mitotic indices less than 50%were
considered ‘‘low,’’ whereas indices more than 50%
were considered ‘‘high.’’
Transient CHFR Transfections
A full-length CHFR cDNA clone was generously
provided by Scholnick and Halazonetis [2]. CHFR
cDNA was cloned into the HindIII and NotI sites of
retroviral pLNCX2 vector (BD Biosciences Clontech,
Palo Alto, CA). The packaging cell line PT67 was
transfected with 6 mg of DNA and 12 mL of FuGENE6
(Roche, Indianapolis, IN).Hs578T cellswere infected
with supernatants from PT67 cells transfected with
retroviral empty pLNCX2 vector, pLNCX2-CHFR,
and pLNCX2-LacZ constructs. The medium was re-
placed with fresh medium and nocodazole was
added 36 h after infection [2]. The mitotic index
was determined as described. RNA was isolated and
cDNA was synthesized with RNeasy and Omniscript
RT kits (Qiagen) to determine levels of CHFR expres-
sion. CHFR and GAPDHwere co-amplified in a semi-
quantitative RT-PCR reaction and CHFR/GAPDH
ratios were calculated following methods previously
described [27]. X-gal staining was performed by
standard methods as a control for infection effi-
ciency in the pLNCX2-LacZ infected Hs578T cells.
Cell Synchronization and Flow Cytometric
Analysis of Cell Cycle
Cells were synchronized at G1/S as described [2].
1106 control or nocodazole-treated cells were
collected and resuspended in 0.1% sodium citrate,
0.1% Triton X, 100 mg/mL Rnase, and 50 mg/mL
propidium iodide. Cells were then analyzed for DNA
content at the University of Michigan Flow Cyto-
metry Core. Cell-cycle profiles of synchronized cell
lines were also confirmed by flow cytometry. G2-M/
G1 ratios were determined to estimate if cells were
in mitosis. Cell lines with a threefold increase of
G2-M/G1 ratios were considered to be inmitosis after
nocodazole treatment.
Western Blot Analysis
Fifty micrograms of whole cell lysates was used
from breast cancer cell lines. Western blot analysis
was performed as previously described [30]. The fol-
lowing antibodieswereused: rabbit antibody specific
to the phosphorylated inactive form of CDC2 (phos-
pho-CDC2-Tyr15) was purchased from Cell Signal-
ling (Beverly, MA) and used 1:1000 dilution. Mouse
polo-like kinase 1 (PLK1) antibodywas received from
Zymed Laboratories (San Francisco, CA) and used
1:500 dilution. Mouse actin antibody (used as a
loading control) (1:1000), goat antirabbit (1:7500)
and rabbit antimouse antibodies (1:5000 for PLK1
and 1:1200 for actin) were purchased from Sigma.
RESULTS
Expression Analysis of CHFR in Breast Cancer Cells
Northern blot analysis revealed that 12 of 24 breast
cancer cell lines had low or no CHFR expression
(Figure 1). By RT-PCR, we were able to amplify the
CHFR coding regioneven in the cell lines that didnot
show expression by Northern blot analysis, indicat-
ing low level of expression (e.g., DU4475).
Mutation and Methylation Analysis of CHFR
Todetermine if specificmutations inactivateCHFR
or decrease CHFR expression, the coding region of
CHFRwas screened in all 24 breast cancer cell lines by
CSGE. We found several sequence variants, but no
predicted pathogenic alterations were detected in
any of the cell lines (Table 2). Cell lines with low
CHFR expression were then treated with both the
demethylating agent 5-aza-dC and histone deacety-
lase inhibitor TSA. Northern blot analysis revealed
that after 5-aza-dC treatment, CHFR expression
was reactivated in two cell lines (MDA-MB435 and
SUM52) (Figure 2). However, 5-aza-dC and TSA co-
treatment did not cause an enhanced response in
these cells compared to 5-aza-dC treatment only. In
addition, we did not observe any increase of CHFR
expression in the other cell lines with low CHFR
levels after TSA treatment (data not shown).
Functional Analysis of the Early G2/M
Checkpoint in Breast Cancer Cells
Mitotic indices were determined in the 24 breast
cancer cell lines as the percentage of cells that had
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condensed chromosomes after nocodazole treat-
ment (Figure 3). Eleven of 12 (92%) cancer cell lines
with low CHFR expression had high (>50%)-mitotic
indices. The MDA-MB468 was the single exception,
with low CHFR expression and a low mitotic index
after nocodazole treatment. To examine whether
low levels of CHFR expression were associated with
highmitotic indices,we transiently transfected three
low-CHFR–expressing cellswith the retroviral empty
pLNCX2 vector pLNCX2-CHFR and pLNCX2-LacZ
constructs. Hs578T cells were the only successfully
transfected cells. X-gal staining of transient LacZ
transfected cells showed approximately 50% trans-
fection efficiency. Although the level of CHFR in
Hs578T cells as detected by semi-quantitative RT-
PCRwasnot increased to the sameendogenous levels
in high-CHFR cell lines (0.4-fold less), mitotic index
in pLNCX2-CHFR transfected cells was reduced
to 34%, whereas vector-only transfected cells de-
monstrated 85% mitotic index after nocodazole
treatment.
MDA-MB468 had low levels of CHFR transcript,
but, unlike the other 11 cell lines with low-CHFR
expression, this cell line demonstrated a lowmitotic
index after treatment with nocodazole. To delineate
further the dynamics of cell-cycle progression
through G2/M in the low mitotic index cells, we
analyzed the DNA content in these cells by flow
cytometry analysis. The ratios of G2-M (4 N) to G1
(2 N) populations were determined to estimate if
cells were arrested in mitosis or exited mitosis after
nocodazole treatment (Table 3). MCF7, MDA-
MB157, BT474, and SUM102 cell lines had more
than threefold increase of the G2-M/G1 ratios after
nocodazole treatment. However, no significant in-
crease was observed in MDA-MB468, T-47D, BT549,
or SUM225.
In the case of BT474, the mitotic index was 46%,
which was close to our top cut-off value (50%) for
categorizing lines as having low mitotic indices.
Therefore, this cell line required further molecular
characterization. BT474 cells were synchronized
at the G1/S border and nocodazole was introduced
12 h after G1/S release [2]. The phosphorylation
level of CDC2-Tyr 15 did not change in BT474 cells,
Figure 1. Low CHFR (checkpoint with forkhead-associated and
ring finger) expression was detected in 50% (12 of 24) of breast
cancer cell lines by Northern blot analysis. HPV5-24 was a human
papilloma virus (HPV) immortalized mammary cell line and it was
used as a positive control for CHFR expression but was not included
in percentage calculations. Samples with the asterisks had low CHFR
expression relative to other samples and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) expression. The mean CHFR/GAPDH
ratio determined by densitometry was 0.4 for low-CHFR–expressing
cells, whereas it was two for higher CHFR-expressing cells, including
HPV5-24. Hybridization of GAPDH probe was used to assess equal
loading of samples. Ethidium bromide staining of ribosomal RNA on
agarose gels was consistent with both running and loading patterns
of the samples assessed by GAPDH hybridization (data not shown).
Table 2. Sequence Variants Detected by CSGE*
Cell line Nucleotide change Codon change Status
BT20 3175 (A!G) 30 UTR Hemi/homozygous{
SUM159 1794 (T!C) 569 (Leu ! Leu) Heterozygous
MDA-MB361 1794 (T!C) 569 (Leu! Leu) Heterozygous
MDA-MB453 974 (A!C) 295 (Pro! Pro) Heterozygous
1794 (T!C) 569 (Leu! Leu) Heterozygous
MDA-MB468 2714 (G!A) 30 UTR Heterozygous
BT474 974 (A!C) 295 (Pro! Pro) Hemi/homozygous{
1794 (T!C) 569 (Leu! Leu) Hemi/homozygous{
SUM225 974 (A!C) 295 (Pro! Pro) Heterozygous
1794 (T!C) 569 (Leu! Leu) Heterozygous
MDA-MB231 1579 (C! T) 497 (Ala!Val) Heterozygous
SUM185 974 (A!C) 295 (Pro! Pro) Heterozygous
1579 (C! T) 497 (Ala!Val) Heterozygous
1794 (T!C) 569 (Leu! Leu ) Heterozygous
*UTR, untranslated region.
{The genotypes of these cell lines were not known with respect to the number of alleles present; thus it was not clear if these samples
were hemizygous or homozygous for the sequence changes.
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whereas in a high mitotic index, low-CHFR ex-
pressing cell line Hs578T, the level of phosphoryla-
tion after nocodazole treatment decreased (Figure 4).
Five of 12 (42%) breast cancer cell lines (SUM1315,
MDA-MB231, MDA-MB453, SUM185, and SK-BR-3)
that had high levels of CHFR expression, also
demonstrated high mitotic indices in response to
nocodazole.
Expression Analysis for the CHFR Interacting
Protein PLK1
Because the only known CHFR interacting protein
is PLK1, we examined PLK1 levels in the same 24
breast cancer cell lines. Variable levels of PLK1
expression were detected in these breast cancer cell
lines; however, there were no correlating patterns of
PLK1 expression with the response of cells to
nocodazole or with CHFR levels (Figure 5A). When
levels of PLK1 in synchronized cells (Hs578T and
BT474) were examined, no changes were detected
afternocodazole treatment, regardless ofCHFR levels
in these cells (Figure 5B).
DISCUSSION
Studies report that CHFR expression is ubiquitous
in normal human tissues and that lack of CHFR
expression or mutations of CHFR is associated with
early G2/M checkpoint defects in various cancers [2].
Here, we report that 50% (12 of 24) of breast cancer
cell lines had low levels of CHFR expression. No
pathogenic sequence alterations were found in any
of the 24 breast cancer cells. The sequence variant
that caused an amino acid change (Ala497 to Val) in
two high-CHFR–expressing cells was reported to be a
polymorphism [16]. However, we cannot eliminate
the possibility of undetected mutations or altera-
tions. The lack of significant sequence alterations in
any of the cell lines led us to examine the possibility
Figure 2. 5-Aza-20-deoxycytidine (5-aza-dC) treatment reacti-
vated transcription of CHFR in two cells lines that had low-CHFR
levels. Cells were treated with 10 mM 5-aza-dC for 96 h. RNA was
isolated as described and expression of CHFR was detected by
Northern blot analysis.
Figure 3. Eleven of 12 (92%) low-CHFR–expressing cells had high
mitotic indices. Cells were treated with nocodazole and mitotic
indices were determined based on the percentage of cells with
condensed chromosomes. DLD-1 is a colon cancer cell line that lacks
CHFR expression, has a high mitotic index in response to nocodazole
[2], and was used as a control in this experiment but was not
included in percentage calculations. Dark gray bars, cell lines that
had low-CHFR expression and high (more than 50%)-mitotic indices;
white bars, high-CHFR expression, low (less than 50%)-mitotic
indices; horizontally dashed bar, the only cell line that had low CHFR
and low (less than 50%) mitotic index; and diagonally dashed bars,
high-CHFR expression, high (more than 50%)-mitotic indices.
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of hypermethylation or histone modification of
the CHFR promoter in low-CHFR–expressing cell
lines because such alterations are reported as com-
mon mechanisms of CHFR silencing in different
cancer types [16–19]. Data showed that CHFR was
reactivated in two cell lines after treatment with a
demethylating agent, suggesting other mechanisms
to be more common than epigenetic regulation to
account for low CHFR expression in breast cancer
cells.
Lack of CHFR expression or mutations of CHFR
have been associated with high mitotic indices and
abnormal response to mitotic stress in cancer cells
[2,19,31]. Consistent with previous data, 11 of 12
(92%) low-CHFR–expressing breast cancer cell lines
demonstrated high mitotic indices in response to
nocodazole treatment. Transient transfection of
CHFR into Hs578T, a cell line which had low CHFR
expression andahighmitotic index after nocodazole
treatment, lowered the mitotic index after nocoda-
zole treatment, suggesting that the high mitotic
index seen in nocodazole treatedHs578T cells was at
least in part due to low CHFR levels. Among the
other low-CHFR–expressing cells we tried to trans-
fect, Hs578T was the only successfully transfected
cell line. This observation is also consistent with
previous studies reporting difficulty of transfecting
CHFR into mammalian cells and the growth dis-
advantage presumably resulted from CHFR over-
expression [15,19].
The only cell line of 12 with low CHFR expression
that also demonstrated lowmitotic index was MDA-
MB468. Cell-cycle analysis of lowmitotic index cells
after nocodazole treatment revealed that four cell
lines including MDA-MB468 failed to arrest in mito-
sis and had exited mitosis possibly due to defects in
both the early G2/M and spindle checkpoints.
To further characterize ‘‘low’’ and ‘‘high’’ mitotic
index cell lines, dephosphorylation of CDC2 as a
marker of mitotic progression was investigated in
two cell lines from both groups because CHFR delays
dephosphorylation of CDC2 in response to amitotic





MCF7 0.12 0.52 4.3
MDA-MB468 0.89 0.94 1.1
MDA-MB157 0.17 0.71 4.2
BT474 0.29 1.36 4.7
T47D 0.17 0.28 1.6
BT549 0.32 0.37 1.2
SUM102 0.23 0.74 3.2
SUM225 0.11 0.22 2.0
Flow cytometry analysis was used to determine the DNA content
of cell lines. Fold change was calculated as the change in G2-M/
G1 ratios before and after nocodazole treatment.
Figure 4. Western blot analysis showed prolonged cell division
cycle 2 (CDC2) Tyr15 phosphorylation in early G2/M checkpoint
arrested BT474 cells. Decreased phosphorylation was detected in
Hs578T cell line, which had low-CHFR and high mitotic index.
Hs578T and BT474 cells were synchronized at G1/S border by
thymidine and thymidine/deoxyctidine, aphidicolin block. Lysates
were collected at G1/S border, 12 h after G1/S release and after
mitotic stress was induced. Mitotic stress was induced 12 h after G1/S
block [2].
Figure 5. Polo-like kinase 1 (PLK1) levels were independent of
CHFR levels in breast cancer cells. (A) Western blot analysis showed
variable expression of PLK1 in breast cancer cell lines. HPV-
immortalized cell lines were used as controls for PLK1 expression.
(B) PLK1 levels remained the same in synchronized Hs578T and
BT474 cells regardless of CHFR levels in these cells after nocodazole
treatment.
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stress [15]. Inhibitory Tyr15 phosphorylation of
CDC2 was detected in BT474 in support of CHFR-
activated early G2/M checkpoint arrest. The Hs578T
cell line, which had low CHFR expression and dis-
played high mitotic index, demonstrated decreased
Tyr15 phosphorylation of CDC2, indicating activa-
tion of CDC2 and thus mitotic progression.
Interestingly, five of 12 (48%) high-CHFR expres-
sing cell lines also had high mitotic indices, suggest-
ing the presence of other proteins involved in this
early G2/M checkpoint or CHFR inactivation due
to undetected mutations. The only other protein
interacting with CHFR reported to date is PLK1. In
Xenopus cell-free extracts, CHFR can ubiquitinate
PLK1 for degradation through its ubiquitin ligase
activity [15,31]. Therefore, we examined the levels of
PLK1 in the 24 breast cancer cell lines, but no
correlation was found between PLK1 levels and
mitotic index orCHFR. In addition, no changes were
detected in PLK1 levels after nocodazole treatment
that would trigger activation of the CHFR-associated
early G2/M checkpoint in synchronized cells. The
in vitro ubiquitination of PLK1 by CHFR may
actually involve more complex interactions in vivo.
As we begin to understand how this checkpoint
functions, we will be better able to investigate how
the molecular interactions take place in the cell
when the checkpoint is activated.
In this study, we report that low CHFR expression
and highmitotic indices after nocodazole treatment
were common in breast cancer cells. The high
incidence of low CHFR expression associated with
an unexpectedly high percentage of condensed
chromosomes after nocodazole treatment in breast
cancer cell lines may suggest a potential role for
CHFR and the early G2/M checkpoint. CHFR and its
role in the early G2/M checkpoint need to be further
explored to reveal the invivoconditions that activate
this pathway, response of the pathway to different
drugs, and key proteins that may function in this or
related pathways. Analysis of CHFR expression in
additional breast cancer cells, including primary
breast tumors, with a highly specific CHFR antibody
as well as in vivo analysis in animalmodels, will help
elucidate the significance of CHFR alterations in
human breast cancers. Elucidation of this CHFR
checkpoint should help us better understand the
genetic instability commonly observed inmalignant
lesions and may provide important insights for
cancer therapy.
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